Deal Watch: Exelixis Teams With Ipsen For Ex-US Commercialization Of RCC Candidate
Executive Summary
Onxeo acquires signal-interfering DNA repair technology for its orphan oncology focus. Sanofi returns auto-injector product to kaleo after product recall.